For clear cell renal cell carcinoma, gastric cancer, breast cancer and hepatocellular carcinoma (22–25), CXCL13 had good diagnostic and prognostic value, hence may become a candidate biomarker and therapeutic target. This evidence concerns the gene CXCL13 and clear cell renal carcinoma.